Divestment of Crestor in Europe to Grünenthal completed
AstraZeneca has completed the divestment of the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe to Grünenthal GmbH (Grünenthal). Rights in the UK and Spain were not included in the agreement. Financial considerations Under the terms of the agreement, AstraZeneca received a payment of $320m from Grünenthal and may also be eligible for future milestone payments of up to $30m. The upfront payment will be reported in AstraZeneca’s